Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Convertible Debt: 2014-2020

Historic Convertible Debt for Zevra Therapeutics (ZVRA) over the last 4 years, with Dec 2020 value amounting to $67.7 million.

  • Zevra Therapeutics' Convertible Debt fell 12.52% to $67.7 million in Q4 2020 from the same period last year, while for Dec 2020 it was $67.7 million, marking a year-over-year decrease of 12.52%. This contributed to the annual value of $67.7 million for FY2020, which is 12.52% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Convertible Debt of $67.7 million as of Q4 2020, which was down 12.52% from $77.3 million recorded in Q4 2019.
  • Zevra Therapeutics' Convertible Debt's 5-year high stood at $90.8 million during Q3 2016, with a 5-year trough of $67.7 million in Q4 2020.
  • In the last 3 years, Zevra Therapeutics' Convertible Debt had a median value of $77.3 million in 2019 and averaged $78.7 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Convertible Debt soared by 1,118.53% in 2016, and later fell by 19.06% in 2019.
  • Quarterly analysis of 4 years shows Zevra Therapeutics' Convertible Debt stood at $90.8 million in 2016, then reached $78.1 million in 2018, then dropped by 0.98% to $77.3 million in 2019, then fell by 12.52% to $67.7 million in 2020.
  • Its Convertible Debt was $67.7 million in Q4 2020, compared to $77.3 million in Q4 2019 and $70.6 million in Q3 2019.